← All trials
NCT05173441
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2021
- Primary completion
- Jun 20, 2023
- Completion date
- Nov 30, 2023
- First posted
- Dec 30, 2021
- Last posted
- Jan 3, 2022
- Enrollment
- 180
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- wuhan opticsLead sponsor
- Beijing Tiantan Bio Co., LtdCollaborator
- China National Biotec Group Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.